Identification

Name
Thioridazine
Accession Number
DB00679  (APRD00596)
Type
Small Molecule
Groups
Approved, Withdrawn
Description

A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p618).

Thioridazine was withdrawn worldwide in 2005 due to it's association with cardiac arrythmias.

Structure
Thumb
Synonyms
  • 10-[2-(1-methyl-2-piperidyl)ethyl]-2-methylsulfanyl-phenothiazine
  • 2-Methylmercapto-10-(2-(N-methyl-2-piperidyl)ethyl)phenothiazine
  • 3-Methylmercapto-N-(2'-(N-methyl-2-piperidyl)ethyl)phenothiazine
  • Thioridazin
  • Thioridazinum
  • Tioridazina
External IDs
TP-21
Product Ingredients
IngredientUNIICASInChI Key
Thioridazine Hydrochloride4WCI67NK8M130-61-0NZFNXWQNBYZDAQ-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MellarilLiquid30 mgOralNovartis1997-08-152001-07-30Canada
MellarilSuspension10 mgOralNovartis1964-12-312001-07-30Canada
Mellaril Tab 100mgTablet100 mgOralSandoz1959-12-311996-09-05Canada
Mellaril Tab 10mgTablet10 mgOralSandoz1959-12-311997-08-12Canada
Mellaril Tab 200mgTablet200 mgOralSandoz1959-12-311996-09-05Canada
Mellaril Tab 25mgTablet25 mgOralSandoz1959-12-311996-09-05Canada
Mellaril Tab 50mgTablet50 mgOralSandoz1959-12-311996-09-23Canada
Novo-ridazine (thioridazine Oral Suspension) - 2 mg/mlSuspension2 mgOralNovopharm Limited1996-09-182005-08-10Canada
Novo-ridazine 100mgTablet100 mgOralNovopharm Limited1972-12-312005-08-10Canada
Novo-ridazine 10mgTablet10 mgOralNovopharm Limited1972-12-312005-08-10Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Thioridazine HydrochlorideTablet, film coated10 mg/1OralMylan Pharmaceuticals1983-03-15Not applicableUs
Thioridazine HydrochlorideTablet25 mg/1OralRemedy Repack2011-04-042016-10-13Us
Thioridazine HydrochlorideTablet, film coated25 mg/1OralSun Pharmaceutical Industries Limited1988-10-07Not applicableUs
Thioridazine HydrochlorideTablet, film coated50 mg/1OralRemedy Repack2017-10-09Not applicableUs
Thioridazine HydrochlorideTablet, film coated100 mg/1OralMylan Pharmaceuticals1983-11-18Not applicableUs
Thioridazine HydrochlorideTablet, film coated25 mg/1OralMylan Institutional1995-06-12Not applicableUs
Thioridazine HydrochlorideTablet, film coated100 mg/1OralRemedy Repack2016-05-04Not applicableUs
Thioridazine HydrochlorideTablet, film coated25 mg/1OralMylan Pharmaceuticals1983-03-15Not applicableUs
Thioridazine HydrochlorideTablet50 mg/1OralRemedy Repack2011-04-042016-10-13Us
Thioridazine HydrochlorideTablet, film coated50 mg/1OralSun Pharmaceutical Industries Limited1988-10-07Not applicableUs
International/Other Brands
Aldazine / Mallorol / Malloryl / Meleril / Mellaril-S / Mellerets / Mellerette / Melleretten / Melleril / Novoridazine / Orsanil / Ridazin / Ridazine / Sonapax / Thioril
Categories
UNII
N3D6TG58NI
CAS number
50-52-2
Weight
Average: 370.575
Monoisotopic: 370.153740222
Chemical Formula
C21H26N2S2
InChI Key
KLBQZWRITKRQQV-UHFFFAOYSA-N
InChI
InChI=1S/C21H26N2S2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(24-2)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3
IUPAC Name
10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfanyl)-10H-phenothiazine
SMILES
CSC1=CC2=C(SC3=CC=CC=C3N2CCC2CCCCN2C)C=C1

Pharmacology

Indication

For the treatment of schizophrenia and generalized anxiety disorder.

Structured Indications
Pharmacodynamics

Thioridazine is a trifluoro-methyl phenothiazine derivative intended for the management of schizophrenia and other psychotic disorders. Thioridazine has not been shown effective in the management of behaviorial complications in patients with mental retardation.

Mechanism of action

Thioridazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; blocks alpha-adrenergic effect, depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.

TargetActionsOrganism
AD(2) dopamine receptor
antagonist
Human
AD(1A) dopamine receptor
antagonist
Human
AAlpha-1A adrenergic receptor
antagonist
Human
AAlpha-1B adrenergic receptor
antagonist
Human
A5-hydroxytryptamine receptor 2A
antagonist
Human
UPotassium voltage-gated channel subfamily H member 2
inhibitor
Human
Absorption

60%

Volume of distribution
Not Available
Protein binding

95%

Metabolism

Hepatic

Route of elimination
Not Available
Half life

21-25 hours

Clearance
Not Available
Toxicity

LD50=956-1034 mg/kg (Orally in rats); Agitation, blurred vision, coma, confusion, constipation, difficulty breathing, dilated or constricted pupils, diminished flow of urine, dry mouth, dry skin, excessively high or low body temperature, extremely low blood pressure, fluid in the lungs, heart abnormalities, inability to urinate, intestinal blockage, nasal congestion, restlessness, sedation, seizures, shock

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2D6CYP2D6*3Not AvailableC alleleADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*4Not AvailableC alleleADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*5Not AvailableWhole-gene deletionADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*6Not Available1707delTADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*7Not Available2935A>CADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*8Not Available1758G>TADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*11Not Available883G>CADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*12Not Available124G>AADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*13Not AvailableCYP2D7/2D6 hybrid gene structureADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*14ANot Available1758G>AADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*15Not Available137insT, 137_138insTADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*19Not Available2539_2542delAACTADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*20Not Available1973_1974insGADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*21Not Available2573insCADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*31Not Available-1770G>A / -1584C>G  … show all ADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*36Not Available100C>T / -1426C>T  … show all ADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*38Not Available2587_2590delGACTADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*40Not Available1863_1864ins(TTT CGC CCC)2ADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*42Not Available3259_3260insGTADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*44Not Available2950G>CADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*47Not Available100C>T / -1426C>T  … show all ADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*51Not Available-1584C>G / -1235A>G  … show all ADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*56Not Available3201C>TADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*57Not Available100C>T / 310G>T  … show all ADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*62Not Available4044C>TADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*68ANot Available-1426C>T / -1235A>G  … show all ADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*68BNot AvailableSimilar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4.ADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*69Not Available2988G>A / -1426C>T  … show all ADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*92Not Available1995delCADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*100Not Available-1426C>T / -1235A>G  … show all ADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*101Not Available-1426C>T / -1235A>G  … show all ADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*9Not Available2615-2617delAAGADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*10Not Available100C>T / 1661G>C  … show all ADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*14BNot Available1758G>AADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*17Not Available1023C>T / 2850C>TADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*18Not Available4133dupGTGCCCACTADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*29Not Available1659G>A / 1661G>C  … show all ADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*41Not Available2988G>AADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*49Not Available100C>T / -1426C>T  … show all ADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*50Not Available1720A>CADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*54Not Available100C>T / 1039C>T  … show all ADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*55Not Available1661G>C / 2850C>T  … show all ADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*59Not Available1661G>C / 2291G>A  … show all ADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details
Cytochrome P450 2D6CYP2D6*72Not Available-1426C>T / -1235A>G  … show all ADR InferredReduced CYP2D6 activity associated with Torsades de pointes and/or sudden death.Details

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineThioridazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineThioridazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThioridazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Thioridazine.Experimental, Illicit
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Thioridazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when Thioridazine is combined with 7-Nitroindazole.Experimental
AcebutololThe serum concentration of Thioridazine can be increased when it is combined with Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Aceprometazine.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Thioridazine.Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Thioridazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Thioridazine is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Agomelatine.Approved, Investigational
AjmalineThe serum concentration of Thioridazine can be increased when it is combined with Ajmaline.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Thioridazine is combined with Alaproclate.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Thioridazine is combined with Aldesleukin.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Thioridazine is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Thioridazine.Approved, Investigational
AlgeldrateAlgeldrate can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AliskirenThe risk or severity of adverse effects can be increased when Thioridazine is combined with Aliskiren.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Allopregnanolone.Investigational
AlmagateAlmagate can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AlmasilateAlmasilate can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Thioridazine.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Thioridazine.Approved
AloglutamolAloglutamol can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Thioridazine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Thioridazine.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Thioridazine.Approved, Withdrawn
AluminiumAluminium can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmantadineAmantadine may increase the QTc-prolonging activities of Thioridazine.Approved
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Thioridazine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Amiloride.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Thioridazine.Approved, Withdrawn
AmiodaroneThe serum concentration of Thioridazine can be increased when it is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe serum concentration of Thioridazine can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Thioridazine can be increased when it is combined with Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Thioridazine is combined with Amobarbital.Approved, Illicit
AmodiaquineThe serum concentration of Thioridazine can be increased when it is combined with Amodiaquine.Approved, Investigational
AmoxapineAmoxapine may increase the QTc-prolonging activities of Thioridazine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Amperozide.Experimental
AmphetamineThe serum concentration of Thioridazine can be increased when it is combined with Amphetamine.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Thioridazine.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Thioridazine.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Thioridazine.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Thioridazine is combined with Amyl Nitrite.Approved
AnagrelideAnagrelide may increase the QTc-prolonging activities of Thioridazine.Approved
AntipyrineThe serum concentration of Thioridazine can be increased when it is combined with Antipyrine.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Thioridazine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Apraclonidine.Approved
AprindineThe metabolism of Aprindine can be decreased when combined with Thioridazine.Approved
ArformoterolArformoterol may increase the QTc-prolonging activities of Thioridazine.Approved, Investigational
ArmodafinilThe metabolism of Thioridazine can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololThioridazine may increase the hypotensive activities of Arotinolol.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Thioridazine.Approved, Investigational
ArtemetherThe serum concentration of Thioridazine can be increased when it is combined with Artemether.Approved
ArtemisininThe serum concentration of Thioridazine can be increased when it is combined with Artemisinin.Investigational
ArtemotilThe serum concentration of Thioridazine can be increased when it is combined with Artemotil.Experimental
ArtenimolThe serum concentration of Thioridazine can be increased when it is combined with Artenimol.Approved, Investigational
ArtesunateThe serum concentration of Thioridazine can be increased when it is combined with Artesunate.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Articaine.Approved
AsenapineThe serum concentration of Thioridazine can be increased when it is combined with Asenapine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Thioridazine.Approved, Withdrawn
AtazanavirAtazanavir may increase the QTc-prolonging activities of Thioridazine.Approved, Investigational
AtenololThioridazine may increase the hypotensive activities of Atenolol.Approved
AtorvastatinThe serum concentration of Thioridazine can be increased when it is combined with Atorvastatin.Approved
AtovaquoneThe serum concentration of Thioridazine can be increased when it is combined with Atovaquone.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Azaperone.Investigational, Vet Approved
AzelastineThe serum concentration of Thioridazine can be increased when it is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Thioridazine is combined with Azilsartan medoxomil.Approved
AzithromycinThe metabolism of Thioridazine can be decreased when combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Thioridazine is combined with Baclofen.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Thioridazine.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Thioridazine is combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Thioridazine.Approved
BedaquilineBedaquiline may increase the QTc-prolonging activities of Thioridazine.Approved
BefunololThioridazine may increase the hypotensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Thioridazine is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Bendroflumethiazide.Approved
BenperidolThe risk or severity of adverse effects can be increased when Thioridazine is combined with Benperidol.Investigational
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Thioridazine.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Benzocaine.Approved
BenzphetamineThioridazine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Thioridazine.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Thioridazine.Approved, Withdrawn
BetaxololThe serum concentration of Thioridazine can be increased when it is combined with Betaxolol.Approved
BevantololThioridazine may increase the hypotensive activities of Bevantolol.Approved
BezitramideThioridazine may increase the hypotensive activities of Bezitramide.Experimental, Illicit, Withdrawn
BicalutamideThe serum concentration of Thioridazine can be increased when it is combined with Bicalutamide.Approved
BiperidenThe serum concentration of Thioridazine can be increased when it is combined with Biperiden.Approved, Investigational
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Thioridazine.Approved
BopindololThioridazine may increase the hypotensive activities of Bopindolol.Approved
BortezomibThe serum concentration of Thioridazine can be increased when it is combined with Bortezomib.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Thioridazine is combined with Bretylium.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Thioridazine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Bromazepam.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Thioridazine is combined with Bromisoval.Experimental
BromocriptineThe therapeutic efficacy of Thioridazine can be decreased when used in combination with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Thioridazine is combined with Bromperidol.Investigational
BrompheniramineThe serum concentration of Thioridazine can be increased when it is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololThioridazine may increase the hypotensive activities of Bucindolol.Investigational
BufuralolThe metabolism of Bufuralol can be decreased when combined with Thioridazine.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Bumetanide.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Thioridazine.Approved, Investigational
BupranololThioridazine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThioridazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Thioridazine can be increased when it is combined with Bupropion.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Thioridazine.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Thioridazine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Thioridazine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Thioridazine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Thioridazine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Thioridazine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Thioridazine.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Thioridazine.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Thioridazine.Approved
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CanagliflozinThe risk or severity of adverse effects can be increased when Thioridazine is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Thioridazine is combined with Candesartan.Approved
CanertinibThe risk or severity of adverse effects can be increased when Thioridazine is combined with Canertinib.Investigational
CaptoprilThe metabolism of Captopril can be decreased when combined with Thioridazine.Approved
CarbamazepineThe metabolism of Thioridazine can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Thioridazine.Approved
CarbinoxamineThe serum concentration of Thioridazine can be increased when it is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Thioridazine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Thioridazine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Thioridazine is combined with Carisoprodol.Approved
CarteololThe serum concentration of Thioridazine can be increased when it is combined with Carteolol.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Thioridazine.Approved, Investigational
CelecoxibThe serum concentration of Thioridazine can be increased when it is combined with Celecoxib.Approved, Investigational
CeliprololThioridazine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Thioridazine.Approved, Vet Approved
CeritinibCeritinib may increase the QTc-prolonging activities of Thioridazine.Approved
CerivastatinThe serum concentration of Thioridazine can be increased when it is combined with Cerivastatin.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Cetirizine.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Thioridazine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Thioridazine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Thioridazine can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Thioridazine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Chloroprocaine.Approved
ChloroquineThe serum concentration of Thioridazine can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineChlorphenamine may increase the arrhythmogenic activities of Thioridazine.Approved
ChlorphentermineThioridazine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorproguanilThe serum concentration of Thioridazine can be increased when it is combined with Chlorproguanil.Investigational
ChlorpromazineThe serum concentration of Thioridazine can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Chlorthalidone.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Thioridazine.Approved
CholecalciferolThe serum concentration of Thioridazine can be increased when it is combined with Cholecalciferol.Approved, Nutraceutical
CilazaprilThe risk or severity of adverse effects can be increased when Thioridazine is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Thioridazine.Approved, Investigational
CilostazolThe metabolism of Cilostazol can be decreased when combined with Thioridazine.Approved
CimetidineThe serum concentration of Thioridazine can be increased when it is combined with Cimetidine.Approved
CinacalcetThe serum concentration of Thioridazine can be increased when it is combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Cinchocaine.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Thioridazine.Approved, Investigational
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Thioridazine.Approved, Investigational
CisaprideThe serum concentration of Thioridazine can be increased when it is combined with Cisapride.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Thioridazine can be increased when it is combined with Citalopram.Approved
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Thioridazine.Approved
ClemastineThe serum concentration of Thioridazine can be increased when it is combined with Clemastine.Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Thioridazine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Thioridazine is combined with Clidinium.Approved
ClobazamThe serum concentration of Thioridazine can be increased when it is combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Thioridazine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Thioridazine is combined with clomethiazole.Investigational
ClomipramineThe serum concentration of Thioridazine can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Clonazepam.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Thioridazine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Thioridazine is combined with Clopenthixol.Experimental
CloranololThioridazine may increase the hypotensive activities of Cloranolol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Thioridazine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Clothiapine.Experimental
ClotrimazoleThe serum concentration of Thioridazine can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Thioridazine can be increased when it is combined with Clozapine.Approved
CocaineThe serum concentration of Thioridazine can be increased when it is combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Thioridazine.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Thioridazine.Approved, Investigational
CrizotinibCrizotinib may increase the QTc-prolonging activities of Thioridazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Cyclizine.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Thioridazine.Approved
Cycloguanil embonateThe serum concentration of Thioridazine can be increased when it is combined with Cycloguanil embonate.Experimental
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Thioridazine.Approved, Investigational
CyclosporineThe serum concentration of Thioridazine can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Thioridazine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Thioridazine can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Dantrolene.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Thioridazine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Thioridazine is combined with Dapiprazole.Approved
DapoxetineDapoxetine may increase the arrhythmogenic activities of Thioridazine.Investigational
DapsoneThe serum concentration of Thioridazine can be increased when it is combined with Dapsone.Approved, Investigational
DarifenacinThe serum concentration of Thioridazine can be increased when it is combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Thioridazine can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Thioridazine.Approved
DasatinibDasatinib may increase the QTc-prolonging activities of Thioridazine.Approved, Investigational
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Thioridazine.Approved, Investigational
DeferasiroxThe serum concentration of Thioridazine can be increased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Thioridazine.Approved
DelavirdineThe serum concentration of Thioridazine can be increased when it is combined with Delavirdine.Approved
DeramciclaneThe serum concentration of Thioridazine can be increased when it is combined with Deramciclane.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Thioridazine.Approved
DesipramineThe serum concentration of Thioridazine can be increased when it is combined with Desipramine.Approved
DesloratadineThe serum concentration of Thioridazine can be increased when it is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Thioridazine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Detomidine.Vet Approved
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Thioridazine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Dexbrompheniramine.Approved
Dexchlorpheniramine maleateThe serum concentration of Thioridazine can be increased when it is combined with Dexchlorpheniramine maleate.Approved
DexfenfluramineThe serum concentration of Thioridazine can be increased when it is combined with Dexfenfluramine.Approved, Illicit, Investigational, Withdrawn
DexmedetomidineThe serum concentration of Thioridazine can be increased when it is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe serum concentration of Thioridazine can be increased when it is combined with Dexmethylphenidate.Approved
DextroamphetamineThe serum concentration of Thioridazine can be increased when it is combined with Dextroamphetamine.Approved, Illicit
DextromethorphanThe serum concentration of Thioridazine can be increased when it is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe serum concentration of Thioridazine can be increased when it is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Dezocine.Approved, Investigational
DiacereinThe serum concentration of Thioridazine can be increased when it is combined with Diacerein.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Diazepam.Approved, Illicit, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Diclofenamide.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Thioridazine is combined with Diethyl ether.Experimental
DiethylpropionThioridazine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Thioridazine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Thioridazine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Thioridazine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe serum concentration of Thioridazine can be increased when it is combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Thioridazine is combined with Dimenhydrinate.Approved
Dimethyl sulfoxideThe serum concentration of Thioridazine can be increased when it is combined with Dimethyl sulfoxide.Approved, Vet Approved
DinutuximabThe risk or severity of adverse effects can be increased when Thioridazine is combined with Dinutuximab.Approved
DiphenhydramineThe serum concentration of Thioridazine can be increased when it is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Thioridazine is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Thioridazine is combined with Dipyridamole.Approved
DisopyramideDisopyramide may increase the QTc-prolonging activities of Thioridazine.Approved
DisulfiramThe serum concentration of Thioridazine can be increased when it is combined with Disulfiram.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Dixyrazine.Experimental
DofetilideDofetilide may increase the QTc-prolonging activities of Thioridazine.Approved
DolasetronThe serum concentration of Thioridazine can be increased when it is combined with Dolasetron.Approved
DomperidoneThe metabolism of Domperidone can be decreased when combined with Thioridazine.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Thioridazine.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Thioridazine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Thioridazine is combined with Doramectin.Vet Approved
DosulepinThe serum concentration of Thioridazine can be increased when it is combined with Dosulepin.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Thioridazine.Approved
DoxepinThe serum concentration of Thioridazine can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Thioridazine can be increased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe serum concentration of Thioridazine can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Thioridazine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.Approved, Illicit
DronedaroneThe serum concentration of Thioridazine can be increased when it is combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Thioridazine is combined with Drotebanol.Experimental, Illicit
DuloxetineThioridazine may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Thioridazine can be increased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Thioridazine.Approved
EletriptanThe metabolism of Eletriptan can be decreased when combined with Thioridazine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Thioridazine.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Eltanolone.Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Thioridazine is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Thioridazine is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Thioridazine.Approved
EnasidenibThe serum concentration of Thioridazine can be increased when it is combined with Enasidenib.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Thioridazine.Approved, Investigational, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Thioridazine.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe serum concentration of Thioridazine can be increased when it is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Thioridazine can be increased when it is combined with Enzalutamide.Approved
EpanololThioridazine may increase the hypotensive activities of Epanolol.Experimental
EpinastineThe serum concentration of Thioridazine can be increased when it is combined with Epinastine.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Thioridazine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Thioridazine is combined with Eprosartan.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Thioridazine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Thioridazine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Thioridazine.Approved
EribulinEribulin may increase the QTc-prolonging activities of Thioridazine.Approved, Investigational
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Thioridazine.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Thioridazine.Approved, Vet Approved
EscitalopramThe serum concentration of Thioridazine can be increased when it is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Thioridazine can be decreased when combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Thioridazine.Investigational
EsmololThioridazine may increase the hypotensive activities of Esmolol.Approved
EsomeprazoleThe metabolism of Thioridazine can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Thioridazine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Thioridazine is combined with Etacrynic acid.Approved
EthanolThioridazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Thioridazine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Thioridazine is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Etoperidone.Withdrawn
EtoricoxibThe serum concentration of Thioridazine can be increased when it is combined with Etoricoxib.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe metabolism of Thioridazine can be decreased when combined with Etravirine.Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Thioridazine.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Thioridazine.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Thioridazine.Approved
FelodipineThe serum concentration of Thioridazine can be increased when it is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineThe serum concentration of Thioridazine can be increased when it is combined with Fenfluramine.Illicit, Investigational, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Thioridazine.Approved
FentanylThe risk or severity of adverse effects can be increased when Thioridazine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Thioridazine.Approved
FexofenadineThe serum concentration of Thioridazine can be increased when it is combined with Fexofenadine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Thioridazine.Approved, Investigational
FingolimodFingolimod may increase the QTc-prolonging activities of Thioridazine.Approved, Investigational
FlecainideThe serum concentration of Thioridazine can be increased when it is combined with Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Thioridazine is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Fluanisone.Experimental
FluconazoleFluconazole may increase the QTc-prolonging activities of Thioridazine.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Thioridazine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Flunitrazepam.Approved, Illicit
FluoxetineFluoxetine may increase the QTc-prolonging activities of Thioridazine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Thioridazine is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Thioridazine can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Thioridazine is combined with Fluticasone propionate.Approved
FluvastatinThe serum concentration of Thioridazine can be increased when it is combined with Fluvastatin.Approved
FluvoxamineThe serum concentration of Thioridazine can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Thioridazine.Approved, Investigational
FoscarnetFoscarnet may increase the QTc-prolonging activities of Thioridazine.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Thioridazine is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Thioridazine can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Thioridazine is combined with Fospropofol.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Thioridazine.Approved, Investigational
FurosemideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Thioridazine is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Thioridazine is combined with Gabapentin Enacarbil.Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Thioridazine.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Thioridazine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Thioridazine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GefitinibThe serum concentration of Thioridazine can be increased when it is combined with Gefitinib.Approved, Investigational
GemfibrozilThe metabolism of Thioridazine can be decreased when combined with Gemfibrozil.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Thioridazine.Approved, Investigational
GepefrineThioridazine may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Thioridazine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Glutethimide.Approved, Illicit
Glycerol PhenylbutyrateThe serum concentration of Thioridazine can be increased when it is combined with Glycerol Phenylbutyrate.Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Thioridazine.Approved
GranisetronThe serum concentration of Thioridazine can be increased when it is combined with Granisetron.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Halazepam.Approved, Illicit, Withdrawn
HalofantrineThe serum concentration of Thioridazine can be increased when it is combined with Halofantrine.Approved
HaloperidolThe serum concentration of Thioridazine can be increased when it is combined with Haloperidol.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Thioridazine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Thioridazine is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Thioridazine is combined with Hexobarbital.Approved
HistamineThe serum concentration of Thioridazine can be increased when it is combined with Histamine.Approved, Investigational
HistrelinHistrelin may increase the QTc-prolonging activities of Thioridazine.Approved
HydralazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThioridazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Thioridazine.Approved, Investigational
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Thioridazine.Approved, Illicit
HydrotalciteHydrotalcite can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
HydroxyamphetamineThioridazine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxychloroquineThe serum concentration of Thioridazine can be increased when it is combined with Hydroxychloroquine.Approved
HydroxyureaThe serum concentration of Thioridazine can be increased when it is combined with Hydroxyurea.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Thioridazine.Approved, Investigational
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Thioridazine.Approved
IbutilideIbutilide may increase the QTc-prolonging activities of Thioridazine.Approved
IdarubicinThe serum concentration of Thioridazine can be increased when it is combined with Idarubicin.Approved
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Thioridazine.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Thioridazine.Approved, Investigational
ImatinibThe serum concentration of Thioridazine can be increased when it is combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Thioridazine.Investigational
ImipramineThe serum concentration of Thioridazine can be increased when it is combined with Imipramine.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Thioridazine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Thioridazine.Approved
IndenololThioridazine may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Thioridazine can be increased when it is combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Thioridazine is combined with Indiplon.Investigational
indisulamThe serum concentration of Thioridazine can be increased when it is combined with indisulam.Investigational
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Thioridazine.Withdrawn
Iofetamine I-123Thioridazine may decrease the stimulatory activities of Iofetamine I-123.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Thioridazine.Approved
IrbesartanThe serum concentration of Thioridazine can be increased when it is combined with Irbesartan.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Thioridazine.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Thioridazine.Approved, Vet Approved
IsoniazidThe serum concentration of Thioridazine can be increased when it is combined with Isoniazid.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Thioridazine is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Thioridazine is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the QTc-prolonging activities of Thioridazine.Approved
ItraconazoleThe serum concentration of Thioridazine can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Thioridazine.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Thioridazine.Approved
KetamineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe serum concentration of Thioridazine can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolThe serum concentration of Thioridazine can be increased when it is combined with Labetalol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Thioridazine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Lamotrigine.Approved, Investigational
LandiololThioridazine may increase the hypotensive activities of Landiolol.Investigational
LansoprazoleThe serum concentration of Thioridazine can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Thioridazine.Approved, Investigational
LenvatinibLenvatinib may increase the QTc-prolonging activities of Thioridazine.Approved
LercanidipineThe serum concentration of Thioridazine can be increased when it is combined with Lercanidipine.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Thioridazine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Levetiracetam.Approved, Investigational
LevobunololThioridazine may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Levocetirizine.Approved
LevodopaThioridazine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Thioridazine.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Thioridazine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Thioridazine.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Thioridazine is combined with Levorphanol.Approved
LevosalbutamolThe serum concentration of Thioridazine can be increased when it is combined with Levosalbutamol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Thioridazine.Approved, Investigational
LidocaineThe serum concentration of Thioridazine can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Thioridazine.Approved, Investigational
LisdexamfetamineThioridazine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Thioridazine is combined with Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Thioridazine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Thioridazine.Approved
LobeglitazoneThe metabolism of Thioridazine can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Thioridazine is combined with Lofentanil.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Thioridazine.Approved, Investigational
LomustineThe serum concentration of Thioridazine can be increased when it is combined with Lomustine.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Thioridazine.Approved
LopinavirThe serum concentration of Thioridazine can be increased when it is combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Loprazolam.Experimental
LoratadineThe serum concentration of Thioridazine can be increased when it is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Thioridazine.Approved
LorcaserinThe serum concentration of Thioridazine can be increased when it is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Lormetazepam.Approved
LosartanThe risk or severity of adverse effects can be increased when Thioridazine is combined with Losartan.Approved
LovastatinThe serum concentration of Thioridazine can be increased when it is combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Thioridazine.Approved
LuliconazoleThe serum concentration of Thioridazine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Thioridazine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Thioridazine can be increased when it is combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Lurasidone.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium HydroxideMagnesium Hydroxide can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ManidipineThe serum concentration of Thioridazine can be increased when it is combined with Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Thioridazine is combined with Mannitol.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Thioridazine.Approved
MebicarThe risk or severity of adverse effects can be increased when Thioridazine is combined with Mebicar.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Mecamylamine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Medetomidine.Vet Approved
MefloquineThe serum concentration of Thioridazine can be increased when it is combined with Mefloquine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Thioridazine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Melperone.Approved, Investigational
MephedroneThioridazine may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineThioridazine may decrease the stimulatory activities of Mephentermine.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Thioridazine.Investigational, Withdrawn
MepindololThioridazine may increase the hypotensive activities of Mepindolol.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Thioridazine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Thioridazine is combined with Meptazinol.Experimental
MepyramineThe serum concentration of Thioridazine can be increased when it is combined with Mepyramine.Approved, Vet Approved
MequitazineThioridazine may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Thioridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Metaxalone.Approved
MethadoneThe serum concentration of Thioridazine can be increased when it is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Thioridazine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineThe serum concentration of Thioridazine can be increased when it is combined with Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe serum concentration of Thioridazine can be increased when it is combined with Methazolamide.Approved
MethimazoleThe serum concentration of Thioridazine can be increased when it is combined with Methimazole.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Thioridazine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Thioridazine.Approved
MethotrimeprazineThioridazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxsalenThe serum concentration of Thioridazine can be increased when it is combined with Methoxsalen.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Thioridazine.Approved, Investigational, Vet Approved
MethoxyphenamineThioridazine may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Methyclothiazide.Approved
Methyl salicylateThe serum concentration of Thioridazine can be increased when it is combined with Methyl salicylate.Approved, Vet Approved
MethyldopaThe risk or severity of adverse effects can be increased when Thioridazine is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Methylecgonine.Experimental
MethylnaltrexoneThe serum concentration of Thioridazine can be increased when it is combined with Methylnaltrexone.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Thioridazine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Thioridazine is combined with Methylphenobarbital.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Thioridazine.Approved, Illicit, Withdrawn
MetipranololThioridazine may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe serum concentration of Thioridazine can be increased when it is combined with Metoclopramide.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Metolazone.Approved
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Thioridazine.Approved
MetyrosineThioridazine may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Thioridazine can be decreased when combined with Mexiletine.Approved
MianserinThe serum concentration of Thioridazine can be increased when it is combined with Mianserin.Approved, Investigational
MibefradilThe serum concentration of Thioridazine can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Thioridazine can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Midazolam.Approved, Illicit
MidodrineThe serum concentration of Thioridazine can be increased when it is combined with Midodrine.Approved
MidomafetamineThioridazine may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit, Investigational
MidostaurinThe serum concentration of Thioridazine can be increased when it is combined with Midostaurin.Approved
MifepristoneThe serum concentration of Thioridazine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Thioridazine is combined with Milnacipran.Approved
MinaprineThe metabolism of Minaprine can be decreased when combined with Thioridazine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Thioridazine is combined with Minoxidil.Approved
MirabegronThe serum concentration of Thioridazine can be increased when it is combined with Mirabegron.Approved
MirtazapineThioridazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MizoribineThe serum concentration of Thioridazine can be increased when it is combined with Mizoribine.Investigational
MMDAThioridazine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe serum concentration of Thioridazine can be increased when it is combined with Moclobemide.Approved
ModafinilThe metabolism of Thioridazine can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Thioridazine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Molindone.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Thioridazine.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Thioridazine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Thioridazine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.Approved, Investigational
NadololThioridazine may increase the hypotensive activities of Nadolol.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Nalbuphine.Approved
NaloxegolThe serum concentration of Thioridazine can be increased when it is combined with Naloxegol.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Thioridazine.Approved, Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Thioridazine.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Thioridazine.Approved, Investigational
NefazodoneThe serum concentration of Thioridazine can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Thioridazine can be increased when it is combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Nesiritide.Approved, Investigational
NetupitantThe metabolism of Netupitant can be decreased when combined with Thioridazine.Approved
NevirapineThe serum concentration of Thioridazine can be increased when it is combined with Nevirapine.Approved
NiacinThe serum concentration of Thioridazine can be increased when it is combined with Niacin.Approved, Investigational, Nutraceutical
NicardipineThe serum concentration of Thioridazine can be increased when it is combined with Nicardipine.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Thioridazine.Approved, Investigational
NicomorphineThioridazine may increase the hypotensive activities of Nicomorphine.Experimental
NicorandilNicorandil may increase the hypotensive activities of Thioridazine.Approved, Investigational
NicotinamideThe serum concentration of Thioridazine can be increased when it is combined with Nicotinamide.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Thioridazine.Approved
NifedipineThe serum concentration of Thioridazine can be increased when it is combined with Nifedipine.Approved
NilotinibThe serum concentration of Thioridazine can be increased when it is combined with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Thioridazine.Approved, Investigational
NimodipineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Nitrazepam.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Thioridazine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Thioridazine.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Thioridazine.Approved, Investigational, Vet Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Thioridazine is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Nitroprusside.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Nitrous oxide.Approved, Vet Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Thioridazine.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Normethadone.Approved, Illicit
NortriptylineThe serum concentration of Thioridazine can be increased when it is combined with Nortriptyline.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Thioridazine.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Thioridazine.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Thioridazine.Approved
OlanzapineThe serum concentration of Thioridazine can be increased when it is combined with Olanzapine.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Thioridazine is combined with Olmesartan.Approved, Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Thioridazine.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Olopatadine.Approved
OmeprazoleThe serum concentration of Thioridazine can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe serum concentration of Thioridazine can be increased when it is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Thioridazine is combined with Opium.Approved, Illicit
OrphenadrineThioridazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Thioridazine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Thioridazine can be decreased when it is combined with Osimertinib.Approved
OspemifeneThe serum concentration of Thioridazine can be increased when it is combined with Ospemifene.Approved
OxamniquineThe serum concentration of Thioridazine can be increased when it is combined with Oxamniquine.Approved
OxazepamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Oxazepam.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Oxethazaine.Approved, Investigational
OxprenololThe serum concentration of Thioridazine can be increased when it is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Oxybuprocaine.Approved
OxybutyninThe serum concentration of Thioridazine can be increased when it is combined with Oxybutynin.Approved, Investigational
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Thioridazine.Approved, Illicit, Investigational
OxymetholoneThe serum concentration of Thioridazine can be increased when it is combined with Oxymetholone.Approved, Illicit
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Thioridazine.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Thioridazine.Approved, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Thioridazine.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Paliperidone.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Thioridazine.Approved, Investigational
PantoprazoleThe metabolism of Thioridazine can be decreased when combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Papaverine.Approved
ParaldehydeThioridazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe serum concentration of Thioridazine can be increased when it is combined with Paroxetine.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Thioridazine.Approved
PazopanibThe serum concentration of Thioridazine can be increased when it is combined with Pazopanib.Approved
Peginterferon alfa-2bThe serum concentration of Thioridazine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThioridazine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Thioridazine is combined with Penfluridol.Experimental
PentamidineThe serum concentration of Thioridazine can be increased when it is combined with Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Thioridazine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Thioridazine.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.Approved
PerazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Perazine.Investigational
PerflutrenPerflutren may increase the QTc-prolonging activities of Thioridazine.Approved
PergolideThe serum concentration of Thioridazine can be increased when it is combined with Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe serum concentration of Thioridazine can be increased when it is combined with Perhexiline.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Thioridazine is combined with Perindopril.Approved
PerospironeThe metabolism of Perospirone can be decreased when combined with Thioridazine.Approved
PerphenazineThe serum concentration of Thioridazine can be increased when it is combined with Perphenazine.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Thioridazine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Thioridazine.Withdrawn
PhenazocineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Thioridazine.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Thioridazine.Approved, Investigational, Withdrawn
PhenibutThe risk or severity of adverse effects can be increased when Thioridazine is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Thioridazine is combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Phenoperidine.Experimental
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Thioridazine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Thioridazine is combined with Phenoxyethanol.Approved
PhentermineThe serum concentration of Thioridazine can be increased when it is combined with Phentermine.Approved, Illicit
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Thioridazine.Approved
Phenylbutyric acidThe serum concentration of Thioridazine can be increased when it is combined with Phenylbutyric acid.Approved, Investigational
PhenytoinThe metabolism of Thioridazine can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe serum concentration of Thioridazine can be increased when it is combined with Pimozide.Approved
PindololThe serum concentration of Thioridazine can be increased when it is combined with Pindolol.Approved
PioglitazoneThe serum concentration of Thioridazine can be increased when it is combined with Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Pipamperone.Approved, Investigational
PiperazineThe metabolism of Piperazine can be decreased when combined with Thioridazine.Approved, Vet Approved
PipotiazineThe serum concentration of Thioridazine can be increased when it is combined with Pipotiazine.Approved, Investigational
PiribedilThe therapeutic efficacy of Thioridazine can be decreased when used in combination with Piribedil.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Thioridazine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Pomalidomide.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Thioridazine.Approved
PosaconazolePosaconazole may increase the QTc-prolonging activities of Thioridazine.Approved, Investigational, Vet Approved
PractololThioridazine may increase the hypotensive activities of Practolol.Approved
PramipexoleThioridazine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Pramocaine.Approved
PravastatinThe serum concentration of Thioridazine can be increased when it is combined with Pravastatin.Approved
PrazepamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Prazepam.Approved, Illicit
PraziquantelThe serum concentration of Thioridazine can be increased when it is combined with Praziquantel.Approved, Vet Approved
PrazosinThe risk or severity of adverse effects can be increased when Thioridazine is combined with Prazosin.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Thioridazine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Prilocaine.Approved
PrimaquineThe serum concentration of Thioridazine can be increased when it is combined with Primaquine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Primidone.Approved, Vet Approved
ProcainamideThe metabolism of Procainamide can be decreased when combined with Thioridazine.Approved
ProcaineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Thioridazine.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Thioridazine.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Thioridazine.Approved, Vet Approved
ProguanilThe serum concentration of Thioridazine can be increased when it is combined with Proguanil.Approved
PromazineThe serum concentration of Thioridazine can be increased when it is combined with Promazine.Approved, Vet Approved
PromethazineThe serum concentration of Thioridazine can be increased when it is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Thioridazine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Proparacaine.Approved, Vet Approved
PropofolThe serum concentration of Thioridazine can be increased when it is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Propoxycaine.Approved
Propoxyphene napsylateThe serum concentration of Thioridazine can be increased when it is combined with Propoxyphene napsylate.Approved
PropranololThe serum concentration of Thioridazine can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Thioridazine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Thioridazine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Thioridazine is combined with PSD502.Investigational
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Thioridazine.Approved
PyrimethamineThe serum concentration of Thioridazine can be increased when it is combined with Pyrimethamine.Approved, Vet Approved
PyronaridineThe serum concentration of Thioridazine can be increased when it is combined with Pyronaridine.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Quazepam.Approved, Illicit
QuetiapineThe serum concentration of Thioridazine can be increased when it is combined with Quetiapine.Approved
QuinacrineThe serum concentration of Thioridazine can be increased when it is combined with Quinacrine.Approved, Investigational
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Thioridazine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Thioridazine is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Thioridazine can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Thioridazine can be increased when it is combined with Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Quinisocaine.Experimental
RabeprazoleThe serum concentration of Thioridazine can be increased when it is combined with Rabeprazole.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Raclopride.Investigational
RadicicolThe serum concentration of Thioridazine can be increased when it is combined with Radicicol.Experimental
RamelteonThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ramelteon.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ramipril.Approved
RanitidineThe serum concentration of Thioridazine can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Thioridazine can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Thioridazine.Approved
ReboxetineThe serum concentration of Thioridazine can be increased when it is combined with Reboxetine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Thioridazine is combined with Remifentanil.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Thioridazine.Approved, Withdrawn
repinotanThe metabolism of repinotan can be decreased when combined with Thioridazine.Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Thioridazine.Approved, Investigational
RheinThe serum concentration of Thioridazine can be increased when it is combined with Rhein.Experimental
RifampicinThe metabolism of Thioridazine can be increased when combined with Rifampicin.Approved
RilpivirineRilpivirine may increase the QTc-prolonging activities of Thioridazine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Thioridazine is combined with Riociguat.Approved
RisperidoneThioridazine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ritanserin.Investigational
RitobegronThioridazine may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe serum concentration of Thioridazine can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe serum concentration of Thioridazine can be increased when it is combined with Rivastigmine.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Thioridazine.Approved
RolapitantThe serum concentration of Thioridazine can be increased when it is combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Romifidine.Vet Approved
RopiniroleThioridazine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Thioridazine.Approved
RosiglitazoneThe serum concentration of Thioridazine can be increased when it is combined with Rosiglitazone.Approved, Investigational
RotigotineThioridazine may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Rucaparib can be decreased when combined with Thioridazine.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Thioridazine.Approved
RupatadineThe metabolism of Rupatadine can be decreased when combined with Thioridazine.Approved
RutinThe serum concentration of Thioridazine can be increased when it is combined with Rutin.Experimental, Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Thioridazine.Approved
SalbutamolSalbutamol may increase the QTc-prolonging activities of Thioridazine.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Thioridazine.Approved
SaquinavirThe serum concentration of Thioridazine can be increased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Thioridazine.Approved, Vet Approved
SelegilineThe serum concentration of Thioridazine can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Sepranolone.Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Thioridazine.Approved, Investigational, Withdrawn
SertralineThe serum concentration of Thioridazine can be increased when it is combined with Sertraline.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Thioridazine.Approved, Vet Approved
SildenafilThe serum concentration of Thioridazine can be increased when it is combined with Sildenafil.Approved, Investigational
SimeprevirThe metabolism of Thioridazine can be decreased when combined with Simeprevir.Approved
SimvastatinThe serum concentration of Thioridazine can be increased when it is combined with Simvastatin.Approved
SinefunginThe serum concentration of Thioridazine can be increased when it is combined with Sinefungin.Experimental
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Thioridazine.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Thioridazine.Approved
SorafenibThe serum concentration of Thioridazine can be increased when it is combined with Sorafenib.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Thioridazine is combined with Sotalol.Approved
SparteineThe serum concentration of Thioridazine can be increased when it is combined with Sparteine.Experimental
SpironolactoneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Spironolactone.Approved
StiripentolThe serum concentration of Thioridazine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Thioridazine.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Thioridazine is combined with Sufentanil.Approved, Investigational
SulconazoleThe serum concentration of Thioridazine can be increased when it is combined with Sulconazole.Approved
SulfadoxineThe serum concentration of Thioridazine can be increased when it is combined with Sulfadoxine.Approved, Investigational
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Thioridazine.Approved
SulfametopyrazineThe serum concentration of Thioridazine can be increased when it is combined with Sulfametopyrazine.Approved, Withdrawn
SulfanilamideThe serum concentration of Thioridazine can be increased when it is combined with Sulfanilamide.Approved
SulfaphenazoleThe serum concentration of Thioridazine can be increased when it is combined with Sulfaphenazole.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Thioridazine.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Thioridazine.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Thioridazine.Approved, Investigational
SuvorexantThioridazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
tafenoquineThe serum concentration of Thioridazine can be increased when it is combined with tafenoquine.Investigational
TalinololThioridazine may increase the hypotensive activities of Talinolol.Investigational
TamoxifenThe serum concentration of Thioridazine can be increased when it is combined with Tamoxifen.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Thioridazine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Thioridazine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Thioridazine is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Thioridazine.Approved
TegaserodThe serum concentration of Thioridazine can be increased when it is combined with Tegaserod.Investigational, Withdrawn
TelavancinTelavancin may increase the QTc-prolonging activities of Thioridazine.Approved
TelithromycinThe serum concentration of Thioridazine can be increased when it is combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Thioridazine is combined with Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Thioridazine.Approved
TemsirolimusThe serum concentration of Thioridazine can be increased when it is combined with Temsirolimus.Approved
Tenofovir disoproxilThe metabolism of Thioridazine can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Thioridazine is combined with Terazosin.Approved
TerbinafineThe serum concentration of Thioridazine can be increased when it is combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Thioridazine.Approved
TerfenadineThe serum concentration of Thioridazine can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Thioridazine can be decreased when it is combined with Teriflunomide.Approved
TertatololThioridazine may increase the hypotensive activities of Tertatolol.Experimental
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Thioridazine.Investigational
TetrabenazineThe serum concentration of Tetrabenazine can be increased when it is combined with Thioridazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Thioridazine is combined with Tetrodotoxin.Investigational
ThalidomideThioridazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Thioridazine.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thioridazine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thioridazine is combined with Thiopental.Approved, Vet Approved
ThiothixeneThe serum concentration of Thioridazine can be increased when it is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Tiapride.Approved, Investigational
TicagrelorThe serum concentration of Thioridazine can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe serum concentration of Thioridazine can be increased when it is combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Tilidine.Experimental
TimololThe serum concentration of Thioridazine can be increased when it is combined with Timolol.Approved
TioconazoleThe serum concentration of Thioridazine can be increased when it is combined with Tioconazole.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Thioridazine.Approved
TipranavirThe serum concentration of Thioridazine can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Thioridazine.Approved
TolazolineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Thioridazine is combined with Tolcapone.Approved, Withdrawn
TolterodineTolterodine may increase the QTc-prolonging activities of Thioridazine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Thioridazine is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Torasemide.Approved
ToremifeneToremifene may increase the QTc-prolonging activities of Thioridazine.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Thioridazine.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Thioridazine.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Thioridazine is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe serum concentration of Thioridazine can be increased when it is combined with Tranylcypromine.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Thioridazine.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Thioridazine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Thioridazine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Triazolam.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Thioridazine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Trifluoperazine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Thioridazine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Thioridazine.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Thioridazine.Approved
TripelennamineThe serum concentration of Thioridazine can be increased when it is combined with Tripelennamine.Approved, Vet Approved
TriprolidineThe serum concentration of Thioridazine can be increased when it is combined with Triprolidine.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Thioridazine.Approved, Vet Approved
TrospiumThe serum concentration of Thioridazine can be increased when it is combined with Trospium.Approved
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Thioridazine.Approved
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Thioridazine.Approved, Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Thioridazine is combined with Valproic Acid.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Thioridazine is combined with Valsartan.Approved, Investigational
VandetanibThioridazine may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Thioridazine.Approved
VenlafaxineThe serum concentration of Thioridazine can be increased when it is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Veralipride.Experimental
VerapamilThe serum concentration of Thioridazine can be increased when it is combined with Verapamil.Approved
VernakalantThe serum concentration of Thioridazine can be increased when it is combined with Vernakalant.Approved, Investigational
VigabatrinThe risk or severity of adverse effects can be increased when Thioridazine is combined with Vigabatrin.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Thioridazine.Approved
VilazodoneThe serum concentration of Thioridazine can be increased when it is combined with Vilazodone.Approved
VinblastineThe serum concentration of Thioridazine can be increased when it is combined with Vinblastine.Approved
VinorelbineThe serum concentration of Thioridazine can be increased when it is combined with Vinorelbine.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Thioridazine is combined with Vinyl ether.Experimental
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Thioridazine.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Thioridazine.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Thioridazine.Approved
XenonThe risk or severity of adverse effects can be increased when Thioridazine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Xylazine.Vet Approved
YohimbineThe serum concentration of Thioridazine can be increased when it is combined with Yohimbine.Approved, Vet Approved
ZafirlukastThe serum concentration of Thioridazine can be increased when it is combined with Zafirlukast.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Thioridazine.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Thioridazine is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Zimelidine.Withdrawn
ZiprasidoneThe serum concentration of Thioridazine can be increased when it is combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Thioridazine.Approved, Investigational
ZolpidemThioridazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Zotepine.Approved, Investigational
ZucapsaicinThe serum concentration of Thioridazine can be increased when it is combined with Zucapsaicin.Approved
ZuclopenthixolThe metabolism of Zuclopenthixol can be decreased when combined with Thioridazine.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB14817
KEGG Drug
D00373
PubChem Compound
5452
PubChem Substance
46509070
ChemSpider
5253
BindingDB
50002338
ChEBI
9566
ChEMBL
CHEMBL479
Therapeutic Targets Database
DAP000476
PharmGKB
PA451666
IUPHAR
100
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Thioridazine
ATC Codes
N05AC02 — Thioridazine
MSDS
Download (44.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0TerminatedNot AvailableHealthy Volunteers1
1CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depressive State / Psychosomatic Disorders / Schizophrenic Disorders1
4Active Not RecruitingTreatmentSchizoaffective Disorders / Schizophrenia and Disorders With Psychotic Features / Schizophrenic Disorders1
Not AvailableCompletedNot AvailableBipolar Disorder (BD) / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Type 2 Diabetes Mellitus1
Not AvailableRecruitingNot AvailableSchizophrenic Disorders1

Pharmacoeconomics

Manufacturers
  • Novartis pharmaceuticals corp
  • Actavis mid atlantic llc
  • Alpharma us pharmaceuticals division
  • Hi tech pharmacal co inc
  • Pharmaceutical assoc inc div beach products
  • Sandoz inc
  • Teva pharmaceuticals usa
  • Wockhardt eu operations (swiss) ag
  • Roxane laboratories inc
  • Ivax pharmaceuticals inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Superpharm corp
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • West ward pharmaceutical corp
Packagers
Dosage forms
FormRouteStrength
LiquidOral30 mg
SuspensionOral10 mg
TabletOral100 mg
TabletOral10 mg
TabletOral25 mg
TabletOral50 mg
TabletOral200 mg
SolutionOral30 mg
SolutionOral5 mg
TabletOral25 mg/1
TabletOral50 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral25 mg/1
Tablet, film coatedOral50 mg/1
SuspensionOral2 mg
Prices
Unit descriptionCostUnit
Thioridazine hcl powder11.16USD g
Thioridazine HCl 200 mg tablet1.14USD tablet
Thioridazine HCl 150 mg tablet1.01USD tablet
Thioridazine HCl 100 mg tablet0.69USD tablet
Thioridazine 100 mg tablet0.67USD tablet
Thioridazine HCl 50 mg tablet0.61USD tablet
Thioridazine 50 mg tablet0.58USD tablet
Thioridazine HCl 25 mg tablet0.49USD tablet
Thioridazine 25 mg tablet0.47USD tablet
Thioridazine HCl 15 mg tablet0.45USD tablet
Thioridazine HCl 10 mg tablet0.35USD tablet
Thioridazine 10 mg tablet0.33USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)73 °CPhysProp
boiling point (°C)230 °C at 2.00E-02 mm HgPhysProp
water solubility0.0336 mg/LNot Available
logP5.90HANSCH,C ET AL. (1995)
pKa9.5EL TAYAR,N ET AL. (1985)
Predicted Properties
PropertyValueSource
Water Solubility0.000855 mg/mLALOGPS
logP5.93ALOGPS
logP5.47ChemAxon
logS-5.6ALOGPS
pKa (Strongest Basic)8.93ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area6.48 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity113.52 m3·mol-1ChemAxon
Polarizability43.26 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9068
Blood Brain Barrier+0.9901
Caco-2 permeable+0.7912
P-glycoprotein substrateSubstrate0.7863
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IIInhibitor0.9115
Renal organic cation transporterInhibitor0.7943
CYP450 2C9 substrateNon-substrate0.7981
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.5068
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.908
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.7697
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5826
Ames testNon AMES toxic0.8703
CarcinogenicityNon-carcinogens0.9528
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5395 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.906
hERG inhibition (predictor II)Inhibitor0.8384
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (8.15 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0002-9110000000-042dbd4f525abce007c0
GC-MS Spectrum - EI-BGC-MSsplash10-0002-9112000000-03a53f455eb75bee12b1
GC-MS Spectrum - CI-BGC-MSsplash10-00di-4539000000-9b298eff08d8aae4d50c
Mass Spectrum (Electron Ionization)MSsplash10-006t-9552000000-ea4c5c56ee4333d0815a
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00di-0009000000-72ae3160baada68a101c
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00di-1409000000-ca7f19c9476403b237f6
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004j-8920000000-1ac0f55aa083ad77c72b
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-002b-9320000000-494b15b3b671ebe76be9
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-9220000000-e3e4ef2154cbee0f6852
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00di-0109000000-0729d6c8c352282a1d00

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiazines
Sub Class
Phenothiazines
Direct Parent
Phenothiazines
Alternative Parents
Alkyldiarylamines / Diarylthioethers / Thiophenol ethers / Alkylarylthioethers / Piperidines / 1,4-thiazines / Trialkylamines / Sulfenyl compounds / Azacyclic compounds / Organopnictogen compounds
show 1 more
Substituents
Phenothiazine / Alkyldiarylamine / Diarylthioether / Aryl thioether / Tertiary aliphatic/aromatic amine / Thiophenol ether / Alkylarylthioether / Piperidine / Para-thiazine / Benzenoid
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
phenothiazines, piperidines (CHEBI:9566)

Targets

Details
1. D(2) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Seeman P: Atypical neuroleptics: role of multiple receptors, endogenous dopamine, and receptor linkage. Acta Psychiatr Scand Suppl. 1990;358:14-20. [PubMed:1978482]
  2. Assie MB, Sleight AJ, Koek W: Biphasic displacement of [3H]YM-09151-2 binding in the rat brain by thioridazine, risperidone and clozapine, but not by other antipsychotics. Eur J Pharmacol. 1993 Jun 24;237(2-3):183-9. [PubMed:7689973]
  3. Dimpfel W, Spuler M, Wessel K: Different neuroleptics show common dose and time dependent effects in quantitative field potential analysis in freely moving rats. Psychopharmacology (Berl). 1992;107(2-3):195-202. [PubMed:1352051]
  4. Barth VN, Chernet E, Martin LJ, Need AB, Rash KS, Morin M, Phebus LA: Comparison of rat dopamine D2 receptor occupancy for a series of antipsychotic drugs measured using radiolabeled or nonlabeled raclopride tracer. Life Sci. 2006 May 22;78(26):3007-12. Epub 2006 Jan 24. [PubMed:16434058]
  5. Carey GJ, Bergman J: Discriminative-stimulus effects of clozapine in squirrel monkeys: comparison with conventional and novel antipsychotic drugs. Psychopharmacology (Berl). 1997 Aug;132(3):261-9. [PubMed:9292626]
Details
2. D(1A) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Hammock RG, Schroeder SR, Levine WR: The effect of clozapine on self-injurious behavior. J Autism Dev Disord. 1995 Dec;25(6):611-26. [PubMed:8720030]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Sleight AJ, Koek W, Bigg DC: Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors: risperidone is selective for the alpha 1B-adrenoceptors. Eur J Pharmacol. 1993 Jul 20;238(2-3):407-10. [PubMed:7691623]
  2. Cahir M, King DJ: Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat. Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4. [PubMed:15695070]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Cahir M, King DJ: Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat. Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4. [PubMed:15695070]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Andree TH, Mikuni M, Tong CY, Koenig JI, Meltzer HY: Differential effect of subchronic treatment with various neuroleptic agents on serotonin2 receptors in rat cerebral cortex. J Neurochem. 1986 Jan;46(1):191-7. [PubMed:2866233]
  2. Canton H, Verriele L, Millan MJ: Competitive antagonism of serotonin (5-HT)2C and 5-HT2A receptor-mediated phosphoinositide (PI) turnover by clozapine in the rat: a comparison to other antipsychotics. Neurosci Lett. 1994 Nov 7;181(1-2):65-8. [PubMed:7898773]
  3. Burki HR: Binding of psychoactive drugs to rat brain amine receptors, measured ex vivo, and their effects on the metabolism of biogenic amines. Naunyn Schmiedebergs Arch Pharmacol. 1986 Mar;332(3):258-66. [PubMed:2423886]
  4. Costall B, Naylor RJ: Behavioural interactions between 5-hydroxytryptophan, neuroleptic agents and 5-HT receptor antagonists in modifying rodent responding to aversive situations. Br J Pharmacol. 1995 Dec;116(7):2989-99. [PubMed:8680734]
  5. Morisset S, Sahm UG, Traiffort E, Tardivel-Lacombe J, Arrang JM, Schwartz JC: Atypical neuroleptics enhance histamine turnover in brain via 5-Hydroxytryptamine2A receptor blockade. J Pharmacol Exp Ther. 1999 Feb;288(2):590-6. [PubMed:9918563]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the ...
Gene Name
KCNH2
Uniprot ID
Q12809
Uniprot Name
Potassium voltage-gated channel subfamily H member 2
Molecular Weight
126653.52 Da
References
  1. Milnes JT, Witchel HJ, Leaney JL, Leishman DJ, Hancox JC: hERG K+ channel blockade by the antipsychotic drug thioridazine: An obligatory role for the S6 helix residue F656. Biochem Biophys Res Commun. 2006 Dec 8;351(1):273-80. Epub 2006 Oct 23. [PubMed:17056009]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Otani K, Aoshima T: Pharmacogenetics of classical and new antipsychotic drugs. Ther Drug Monit. 2000 Feb;22(1):118-21. [PubMed:10688273]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:41